Clinical Scorecard: FDA monthly preview: Key November decisions to watch
At a Glance
Category
Detail
Condition
FDA regulatory decisions for investigational or supplemental therapies across hematology, oncology, cardiology, neurology, pulmonology, and kidney disease
Key Mechanisms
The article describes therapies with varied mechanisms, including a pyruvate kinase activator, PD-1/VEGF bispecific antibody, ALK inhibitor, estrogen receptor degrader, cardiac myosin inhibitor, glucosylceramide synthase inhibitor, cell therapy, and GM-CSF therapy.
Target Population
Patients with the conditions specified in the applications, including sickle cell disease, selected cancers, obstructive hypertrophic cardiomyopathy, Gaucher disease type 3, muscular dystrophies, and autoimmune pulmonary alveolar proteinosis
Care Setting
FDA review of drug and biologics applications; the article reports trial evidence and anticipated regulatory action dates, not clinical practice recommendations.
Key Highlights
Mitapivat received Priority Review under the accelerated approval pathway for a supplemental application for sickle cell disease, with a November 1, 2026, PDUFA goal date. The phase 3 RISE UP trial evaluated hemoglobin response and annualized sickle cell pain crises.
Ivonescimab and aficamten supplemental applications have November 14, 2026, PDUFA goal dates.
Venglustat received Priority Review for type 3 Gaucher disease. Its phase 3 active-comparator study in patients aged 12 years and older met primary endpoints for ataxia and neurocognitive performance at week 52.
Giredestrant received Priority Review for adjuvant treatment of adults with ER-positive, HER2-negative stage I to III breast cancer; the article reports a 30% reduction in risk of invasive disease recurrence or death versus standard endocrine therapy.
The article lists November 22, 25, 27, and 30, 2026, target dates for applications including deramiocel, molgramostim, BBP-418, neladalkib, bezuclastinib, giredestrant, and other applications described in the article.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Populations described include patients with sickle cell disease; EGFR-mutated or ALK-positive non-small cell lung cancer; ER-positive, HER2-negative breast cancer; gastrointestinal stromal tumors after imatinib; symptomatic obstructive hypertrophic cardiomyopathy; type 3 Gaucher disease; Duchenne or limb-girdle muscular dystrophy; and autoimmune pulmonary alveolar proteinosis.
The article summarizes investigational or supplemental applications and selected trial findings. It does not provide prescribing instructions, dosing, contraindications, or comprehensive safety data.
A splinter injury progressed to finger necrosis in a patient with MDS, despite antibacterial treatment and no clinically apparent systemic dissemination.
